foretinib

Foretinib is an orally available small molecule multikinase inhibitor developed for the treatment of cancer. It targets multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, angiogenesis, and metastasis. Its primary targets include MET (hepatocyte growth factor receptor), vascular endothelial growth factor receptor 2 (VEGFR2), RON, AXL, TIE2, ERK, AKT, platelet-derived growth factor receptor beta (PDGFRB), FMS-like tyrosine kinase 3 (FLT3), and RET kinases. By inhibiting these kinases, foretinib blocks proliferation signals in cancer cells and impairs angiogenesis. The drug was discovered by Exelixis and further developed by GlaxoSmithKline. Foretinib has been investigated in clinical trials for various cancers including breast cancer, renal cell carcinoma (especially papillary subtype), gastric cancer, liver cancer, non-small cell lung cancer, head and neck cancers; however as of late 2015 its development appears to have been discontinued[1][2][3][5][7].

Other names

foretinib